Mechanically, Atractylenolide II suppressed the cell proliferation capacity by decreasing XIST and ROR1 expression, thus efficiently reversing the XIST-induced chemoresistance of CRC cells. The gene discussed is ROR1; the disease is colorectal carcinoma.